ctdna as a recurrence biomarker after resection

Question

Accepted Answer

Summary

The provided passages do not contain published data establishing circulating tumor DNA (ctDNA) as a validated recurrence biomarker after resection. While one study [3] links post-treatment SATa hypomethylation to poor prognosis in patients who underwent surgery, it does not report ctDNA status as the primary predictor of recurrence or survival outcomes. Another passage [2] describes cfDNA profiling for diagnostic discrimination but excludes recurrence data. No efficacy or prognostic statistics for ctDNA-driven recurrence monitoring are available in the provided text.

Evidence

Study [3]: A retrospective analysis of 37 patients with pancreatic ductal adenocarcinoma (PDAC) who underwent surgery or first-line chemotherapy. The study evaluated LINE-1 and satellite alpha (SATa) hypomethylation levels relative to KRAS-mutated ctDNA status. While post-treatment SATa RDL ≥0.150 was associated with poor prognosis (P=0.038), pretreatment LINE-1 and SATa cut-offs did not link to prognosis. The study assessed prognosis in the context of surgery or chemotherapy but does not provide specific recurrence rates or hazard ratios for ctDNA as a standalone biomarker.

Study [2]: A thesis establishing a cfDNA atlas using nucleosome positioning signatures at repetitive elements. It demonstrates that machine learning models can discriminate healthy individuals from patients with pancreatic cancer (among others) using cfDNA features. This work focuses on diagnostic accuracy and pan-cancer/tissue-specific detection rather than post-resection recurrence monitoring.

Caveats

The available evidence is limited by the small sample size of the only relevant clinical study [3] (n=37) and its retrospective design. The study [3] conflates DNA hypomethylation markers with ctDNA status, making it difficult to isolate the predictive value of ctDNA alone for recurrence. Furthermore, passage [2] is a methodological thesis focused on diagnosis, not longitudinal recurrence monitoring. No randomized controlled trials or large-scale prospective cohorts validating ctDNA for post-resection surveillance are cited.